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Although optimists once imagined that serious infec-
tious disease threats would by now be conquered, newly
emerging (e.g., severe acute respiratory syndrome
[SARS]), reemerging (e.g., West Nile virus), and even
deliberately disseminated infectious diseases (e.g., anthrax
bioterrorism) continue to appear throughout the world. Over
the past decade, the global effort to identify and character-
ize infectious agents, decipher the underlying pathways by
which they cause disease, and develop preventive meas-
ures and treatments for many of the world’s most danger-
ous pathogens has resulted in considerable progress.
Intramural and extramural investigators supported by the
National Institute of Allergy and Infectious Diseases
(NIAID) have contributed substantially to this effort. This
overview highlights selected NIAID-sponsored research
advances over the past decade, with a focus on progress
in combating HIV/AIDS, malaria, tuberculosis, influenza,
SARS, West Nile virus, and potential bioterror agents.
Many basic research discoveries have been translated into
novel diagnostics, antiviral and antimicrobial compounds,
and vaccines, often with extraordinary speed.
I
nfectious diseases have been an ever-present threat to
mankind. From the biblical plagues and the Plague of
Athens in ancient times, to the Black Death of the Middle
Ages, the 1918 “Spanish Flu” pandemic, and more recent-
ly, the HIV/AIDS pandemic, infectious diseases have con-
tinued to emerge and reemerge in a manner that defies
accurate predictions (1–3).
The past 10 years (1994–2004) have been no exception,
as many new and reemerging microbial threats have con-
tinued to challenge the public health and infectious disease
research communities worldwide. Since 1994, when
Emerging Infectious Diseases made its publication debut,
significant strides in the global fight against the HIV/AIDS
pandemic have been made. The infectious disease commu-
nity has confronted several other newly emerging
pathogens, such as the severe acute respiratory syn-
drome–associated coronavirus (SARS-CoV), henipavirus-
es (Hendra and Nipah), and, most recently, avian influenza
viruses that have caused illness and deaths in humans with
the threat of evolution into a pandemic (1–3). In addition,
historically established infectious diseases, such as West
Nile fever, human monkeypox, dengue, tuberculosis, and
malaria have reemerged or resurged, sometimes in popula-
tions that previously had been relatively exempt from such
affronts. Over the past decade, strains of common
microbes such as Staphylococcus aureus and
Mycobacterium tuberculosis have continued to develop
resistance to the drugs that once were effective against
them (1–4). Such antimicrobial-resistant microorganisms,
which defy conventional therapies and pose a threat to
public health, underscore the need for a robust pipeline of
new antimicrobial agents based on innovative therapeutic
strategies, new vaccines, and other preventive measures
(3,4).
Perhaps most disturbing, the United States has recently
experienced a deliberately spread infectious disease in the
form of 22 anthrax infections, including 5 anthrax-related
deaths resulting from bioterrorism in 2001 (5). These cases
were accompanied by widespread psychological sequelae
and societal and economic disruptions. 
These emerging and reemerging infectious diseases are
superimposed on a substantial baseline of established
infectious diseases. Although annual deaths and lost years
of healthy life from infectious diseases have decreased
over the past decade, the worldwide impact from infec-
tious diseases remains substantial. Overall, infectious dis-
eases remain the third leading cause of death in the United
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*National Institutes of Health, Bethesda, Maryland, USAStates each year and the second leading cause of death
worldwide (6). As shown in Figure 1, of the estimated 57
million deaths that occur throughout the world each year,
≈15 million, >25%, are directly caused by infectious dis-
eases. Millions more deaths are due to secondary effects of
infections (6).
Infectious diseases also lead to compromised health
and disability, accounting for nearly 30% of all disability-
adjusted life years (DALYs) worldwide (1 disability-
adjusted life year is 1 lost year of healthy life) (6).
Infectious diseases that contribute to the nearly 1.5 billion
total DALYs each year are categorized in Figure 2. 
In the United States, the Centers for Disease Control
and Prevention has devised strategies to prevent, monitor,
and contain disease outbreaks. Within the National
Institutes of Health, the National Institute of Allergy and
Infectious Diseases (NIAID) is the lead agency for infec-
tious disease research. 
Over the past decade, the NIAID budget has quadru-
pled; spending on emerging infectious diseases has
increased from <$50 million in 1994 to >$1.7 billion pro-
jected for 2005, a boost due in large part to increases in
funding for biodefense research (Figure 3). NIAID-sup-
ported intramural and extramural investigators have con-
tributed substantially to the global effort to identify and
characterize infectious agents, decipher the underlying
pathways by which they cause disease, and develop pre-
ventive measures and treatments for many of the world’s
most dangerous pathogens. This review briefly highlights
some of the research strides made by NIAID-supported
investigators during the past decade in preventing and
combating emerging and reemerging infectious diseases
threats. 
HIV/AIDS 
HIV/AIDS has resulted in the death of >20 million per-
sons throughout the world and is the leading cause of death
among persons 15–59 years of age. Approximately 40 mil-
lion persons are estimated to be living with HIV infection
(7). In the United States, an estimated 1 million persons are
infected with HIV, and 40,000 new infections occur each
year. Since its recognition in 1981, the disease has killed
more than half a million people in the United States (8). 
Despite these grim statistics, reason for hope exists.
Basic research has yielded major insights into the patho-
genic mechanisms of HIV disease. This knowledge paved
the way for the development of >20 antiretroviral medica-
tions approved by the Food and Drug Administration
(FDA) that target HIV, as well as novel strategies for pre-
vention and vaccine development (9).
With the use of combinations of drugs that target differ-
ent proteins involved in HIV pathogenesis (a treatment
strategy known as highly active antiretroviral therapy
[HAART]), rates of death and illness in the United States
and other industrialized countries have been dramatically
reduced (7,8) (Figure 4). Although the death rate due to
HIV/AIDS in Europe and North America has fallen by
80% since HAART was introduced, relatively few people
in poor countries have reaped these benefits. New initia-
tives such as the Global Fund to Fight AIDS, Tuberculosis,
and Malaria and the President’s Emergency Plan for AIDS
Relief promise to greatly reduce the disparity between rich
and poor countries with regard to access to HIV treatment,
care, and prevention services (7).
The greatest challenge in HIV/AIDS research remains
developing a vaccine that can either prevent the transmis-
sion of the virus or, failing that, halt progression to AIDS.
Since 1987, NIAID has funded >70 clinical trials evaluat-
ing >50 different HIV vaccine candidates. Unfortunately,
the first large-scale phase 3 trial of an HIV vaccine report-
ed in 2003 had disappointing results (10). Many different
vaccine strategies, including viral and bacterial vectors,
DNA vaccines, viruslike particle vaccines, and peptide
vaccines are being investigated, and ≈15 clinical trials in
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Figure 1. Leading causes of death worldwide (estimates for 2002).
Nearly 15 million (>25%) of the 57 million annual deaths worldwide
are caused by infectious disease (6). 
Figure 2. Leading causes of disability life years (DALYs) due to
infectious and parasitic diseases (2002 estimates). Lower respira-
tory infections, HIV/AIDS, diarrheal diseases, and malaria are
among the infectious diseases that contribute to the most DALYs
lost each year throughout the world (6).humans are under way. The effects of various adjuvants
and different routes of administration also are being tested. 
HIV vaccine developers face formidable scientific
obstacles, including the virus’s genetic diversity and the
lack of a clear understanding of the correlates of protective
immunity in HIV infection (9). Acritical and so far elusive
milestone is the discovery of a stable and immunogenic
conformational epitope of the HIV envelope that would
elicit broadly reactive neutralizing antibodies against pri-
mary isolates of HIV (9). To overcome these challenges,
collaborations involving government, academia, industry,
and philanthropies and new cross-sector partnerships such
as the Global HIVVaccine Enterprise, a virtual consortium
of independent organizations, are being established to
advance HIV vaccine research and foster greater collabo-
ration among HIV vaccine researchers worldwide (11).
Malaria 
The social, economic, and human toll exacted by malar-
ia globally is widespread and profound. Each year, acute
malaria occurs in >300 million people and results in >1
million deaths worldwide. Most of these deaths occur in
young children who live in sub-Saharan Africa (3,6). 
In humans, the disease is caused by one of 4 species of
Plasmodium, a single-cell parasite transmitted by anophe-
line mosquitoes. In 2002, the complete genomic sequence
of Plasmodium falciparum as well as that of the mosquito
vector Anopheles gambiae were completed as the result of
a multinational effort (12,13). With the genomic sequences
of the parasite and its human and mosquito hosts now
available, researchers have powerful tools to further char-
acterize the genes and proteins involved in the life cycle of
the parasite, and they are using this information to design
effective drugs and vaccines. 
Drug-resistant Plasmodium strains are widespread, as
are insecticide-resistant strains of the mosquitoes that
carry the parasites. Mutations in both parasites and mos-
quitoes that confer drug and insecticide resistance have
been identified. For example, genetic analysis and molec-
ular epidemiology studies of P. falciparum have shown
that resistance to chloroquine and other antimalarials is
caused by a mutation in a single gene, called pfcrt (14,15).
This information is being used to track the spread of drug-
resistant strains of the parasite and identify new drug tar-
gets (16). Researchers also are exploiting the new genomic
information to create genetically altered mosquitoes that
resist parasite infection and to develop new compounds
that overcome or avoid resistance to existing pesticides
(17).
Developing an effective antimalarial vaccine has been a
challenge; however, an international research team recent-
ly developed a vaccine that shows promise in preventing
malaria among children in Mozambique. The vaccine pre-
vented infection and severe disease in a substantial per-
centage of children tested, a breakthrough with the poten-
tial of saving millions of lives (18). Specifically, vaccine
efficacy for the first clinical episodes was 29.9% (95%
confidence interval [CI] 11.0–44.8, p = 0.004). Vaccine
efficacy for severe malaria was 57.7% (95% CI 16.2–80.6,
p = 0.019) (18). In addition, at least 35 other malaria vac-
cine candidates have undergone phase 1 clinical trials in
humans, and 13 have moved into more advanced clinical
development (19). Preclinical development of more than a
dozen other candidates is being supported (19). 
Tuberculosis 
Another ancient microbial scourge that has reemerged
in recent years is tuberculosis (TB), caused by infection
with the bacterium Mycobacterium tuberculosis. This
infection is estimated to be prevalent in one third of the
world’s population. From this reservoir, 8 million new
cases of TB develop worldwide each year that carry a
death toll of >2 million (3,6). TB is especially prevalent
among persons infected with HIV. The only currently
available TB vaccine, M. bovis bacillus Calmette-Guérin
(BCG), offers some protection, but its effect diminishes
with time (20). TB drug treatment is effective, but adher-
ence to lengthy therapeutic regimens is difficult to main-
tain, and multidrug-resistant TB is on the rise in many
countries (3,4). 
Researchers are applying state-of-the-art genomic and
postgenomic techniques to identify key molecular path-
ways that could be exploited to develop improved TB
interventions and vaccines (21,22). In 2004, for the first
time in 60 years, 2 new vaccines designed to prevent TB
entered phase 1 clinical trials in the United States (23,24).
Many promising new anti-TB drug candidates also are
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Figure 3. Budget of the National Institute for Allergy and Infectious
Disease (NIAID), FY1994–2005. The overall NIAID budget rose
from $1.06 billion in FY1994 to $4.4 billion (estimated) in FY2005.
Funding for emerging infectious diseases rose from $47.2 million
in FY1994 to $1.74 billion in FY2005 (est.).now entering the drug pipeline (25). Derivatives of known
anti-TB drugs, such as thiolactomycin and ethambutol, are
currently being screened for activity against M. tuberculo-
sis. Preclinical development of a highly promising candi-
date, SQ109 is nearing completion.
Influenza 
Each year, influenza develops in up to 20% of all
Americans, and >200,000 are hospitalized with the dis-
ease. Although influenza is commonplace and generally
self-limited, an estimated 36,000 Americans die each year
from complications of the disease (26). Worldwide, severe
influenza infections develop in 3–5 million people annual-
ly, and 250,000–500,000 deaths occur (27).
Outbreaks of avian influenza recently have drawn
attention worldwide, particularly in Southeast Asia, where
at least 55 persons have been infected and 42 have died
since January 2004. The current strain of H5N1 avian
influenza is highly pathogenic; it has killed millions of
chickens and other birds. Although the virus can cross
species to infect humans, few suspected cases of human-
to-human transmission have been reported (27). However,
the virus could acquire characteristics that allow it to be
readily transmitted among humans, which could cause a
worldwide influenza pandemic, with the potential for
killing millions of people. In 1918, a pandemic of the
“Spanish Flu” killed 20–50 million people worldwide
(26,27). 
Recently, the NIH Influenza Genomics Project was ini-
tiated; it will conduct rapid sequencing of the complete
genomes of the several thousand known avian and human
influenza viruses as well as those that emerge in the
future. Approximately 60 genomes are expected to be
sequenced each month. This project should also illumi-
nate the molecular basis of how new strains of influenza
virus emerge and provide information on characteristics
that contribute to increased virulence. Many researchers
believe that the H5N1 virus shows the greatest potential
for evolving into the next human pandemic strain. Avian
H9N2 viruses also have infected humans and have the
potential to cause a pandemic. To prepare for this possibil-
ity,  the development of vaccines to prevent infection with
H5N1 and H9N2 viral strains is being supported (28).
Researchers also are working to develop a live-attenuated
vaccine candidate directed against each of the 15 hemag-
glutinin proteins that have been isolated, an effort that
may speed the development of a vaccine against a poten-
tial pandemic strain.
Using reverse genetics, researchers developed a geneti-
cally engineered vaccine candidate (called a reference
virus) against H5N1 in a matter of weeks, demonstrating
the power of this technology (29). The new H5N1 candi-
date was tested in animals to confirm that it was no longer
highly pathogenic (29), and vaccine manufacturers are
using the reference virus to develop inactivated vaccines
that will be evaluated in phase 1 and 2 clinical trials.
Reverse genetics also has been used to identify a specific
genetic mutation in a H5N1 viral gene, called PB2, which
makes the virus especially lethal. This discovery may be
useful in designing antiviral drugs and vaccine candidates
(30).
Experiments also are being conducted in which genes
isolated from the 1918 influenza strain are cloned into
avirulent influenza strains. Researchers recently showed
that the hemagglutinin gene from the 1918 virus conferred
a high degree of pathogenicity to avirulent influenza
strains when introduced into mice (31). These recombinant
viruses and others are being evaluated in various animal
models, including nonhuman primates, to further deter-
mine how genes of the 1918 virus contributed to its ability
to spread so rapidly and cause so many deaths, and to
understand the molecular basis for its unprecedented viru-
lence. Previous research (32) established the foundation
for developing a live-attenuated nasal flu vaccine that was
approved by FDA in 2003 for use in healthy adults and
children 5–49 years of age (33).
West Nile Virus 
West Nile virus (WNV), long endemic in Africa, West
Asia, Europe, and the Middle East, represents a reemerg-
ing disease that only recently arrived in the United States.
The virus first appeared in the New York City area in 1999,
where WNV-related disease was reported in 62 persons. It
has continued to spread throughout the United States in
subsequent summers, infecting ever larger populations,
particularly in 2003 (34). Research has led to several
promising vaccine candidates against WNV (35). One of
these, based on a licensed yellow fever vaccine virus that
contains 2 WNV genes, has been tested in nonhuman
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Figure 4. AIDS cases, AIDS deaths, and persons living with AIDS
in the United States, 1981–2003. Over the past decade, the num-
ber of new AIDS cases and deaths due to AIDS has decreased,
while the number of people living with the disease has increased,
due in large part to improvements in diagnosis and treatment.
Estimates adjusted for reporting delays. Source: CDC (8).primates; it is currently being evaluated in human clinical
trials. A second vaccine developed at NIH uses an attenu-
ated dengue virus into which WNV genes have been
inserted. This vaccine protects monkeys and horses against
WNV infection, and a clinical trial is now underway.
Subunit and DNA vaccines against WNV are also in vari-
ous stages of development and testing.
Several innovative therapies also are being tested to
treat persons already infected with WNV. In a clinical trial
at >60 sites across the United States and Canada, the pro-
tective effect of an immunoglobulin product is being test-
ed in hospitalized patients who are at high risk for or who
have WNV encephalitis (36). Technology also has been
developed to screen large numbers of chemical compounds
for antiviral activity. As of February 28, 2005, 1,500 com-
pounds had been screened in vitro, and 2%–3% were
shown to have antiviral activity against WNV. These com-
pounds are undergoing further evaluation in hamster and
mouse models of disease. Partnerships with small biotech-
nology companies have been formed to develop more sen-
sitive and rapid tests for detecting WNV infections. Other
studies are ongoing to evaluate the roles of various mos-
quito vectors and animal reservoirs in virus transmission,
to test novel mosquito control methods, and to limit the
impact of insecticide resistance on mosquito control (37). 
SARS 
The emergence of SARS in Asia in late 2002, and the
speed with which it was characterized and contained,
underscores the importance of cooperation between
researchers and public health officials (38). NIAID is
focusing its resources on developing diagnostics, vaccines,
and novel antiviral compounds to combat SARS-CoV.
Basic research on the pathogenesis of the disease to iden-
tify appropriate targets for therapeutics and vaccines, as
well as clinical studies to test new therapies, is also being
supported. Among many projects that have received sup-
port are the development of a “SARS chip,” a DNA
microarray to rapidly identify SARS sequence variants,
and a SARS diagnostic test based on polymerase chain
reaction technology (38). 
Researchers have developed 2 candidate vaccines,
based on the SARS-CoV spike protein, that protect mice
against SARS (39,40). Another promising vaccine protects
against infection in monkeys when delivered intranasally
(41). Passive immunization as a treatment for SARS
patients is also being investigated. Both mouse and human
antibodies against SARS can prevent infection when intro-
duced into uninfected mice (42,43), and an international
collaboration has developed a rapid method of producing
human anti-SARS antibodies (43). In 2004, in vitro screen-
ing of >20,000 chemicals identified ≈1,500 compounds
with activity against SARS-CoV, at least 1 of which has
been selected by industry as a candidate for further clinical
development (38). 
Potential Bioterror Agents 
The September 11, 2001, attacks on the World Trade
Center and Pentagon, and the subsequent anthrax attacks
that infected 22 people and killed 5, propelled the U.S.
government to expand its biodefense research program
(44). These studies are based on 3 approaches: basic
research aimed at understanding structure, biology, and
mechanisms by which potential bioweapons cause disease;
studies to elucidate how the human immune system
responds to these dangerous pathogens; and development
of the technology to translate these basic studies into safe
and effective countermeasures to detect, prevent, and treat
diseases caused by such pathogens (44). 
At least 60 major NIAID initiatives involving intramu-
ral and extramural scientists and industrial partners were
funded in fiscal years 2002–2004. Among them are fund-
ing for 8 Regional Centers of Excellence for Biodefense
and Emerging Infectious Diseases Research and construc-
tion of 2 National Biocontainment Laboratories and 9
Regional Biocontainment Laboratories. These facilities
will provide the secure space needed to carry out the
nation’s expanded biodefense research program (44). 
The genomes of all biological agents considered to pose
the most severe threats have been sequenced by
researchers (45). In addition, programs have been expand-
ed and contracts awarded to screen new chemical com-
pounds as possible treatments for bioterror attacks. New
animal models have been developed to test promising
drugs, and repositories have been established to catalog
reagents and specimens (44). 
In addition, research to understand the body’s protec-
tive mechanisms against pathogens is being pursued. The
Cooperative Centers for Translational Research on Human
Immunology and Biodefense will focus on studies of the
human immune response to potential agents of bioterror,
while other programs are focused on the innate immune
system and the development of ways to boost innate
immunity (44).  
NIAID also has been very active in vaccine develop-
ment as a biodefense countermeasure (44). The Institute
has supported the development of a next-generation
anthrax vaccine, known as recombinant protective antigen
(rPA); it is undergoing clinical trials, and contracts for the
Strategic National Stockpile to acquire it have recently
been awarded. Several new smallpox vaccines also are
being tested for safety and efficacy. Preliminary studies in
mice and monkeys show that one of these, modified ac-
cinia Ankara (MVA), protects against poxvirus infections
(46,47). Clinical trials of the MVA vaccine are ongoing at
NIAID Vaccine Research Center and elsewhere (44). 
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virus also is under way; human testing of an adenovirus-
vectored Ebola vaccine is planned for 2005 (48). Vaccine
manufacturing and clinical trials also are planned for a
new, recombinant vaccine against plague that is highly
effective in mice and nonhuman primates (49). 
Challenges for the Future
Scientists—government and academic, together with
their industrial partners and international collaborators—
have made great strides over the past 10 years in under-
standing many of the pathogenic mechanisms of emerging
and reemerging infectious diseases. Many of these discov-
eries have been translated into novel diagnostics, antiviral
and antimicrobial compounds, and vaccines, often with
extraordinary speed. 
However many challenges remain. Paramount among
these is developing a safe and effective HIV vaccine. The
evolution of pathogens with resistance to antibacterial and
antiviral agents continues to challenge us to better under-
stand the mechanisms of drug resistance and to devise new
ways to circumvent the problem. These efforts will pave
the way for developing countermeasures against deliber-
ately engineered microbes.
If history is our guide, we can assume that the battle
between the intellect and will of the human species and the
extraordinary adaptability of microbes will be never-end-
ing. To successfully fight our microbial foes, we must con-
tinue to vigorously pursue research on the basic
mechanisms that underlie microbial pathogenesis and
develop novel strategies to outwit theses ingenious oppo-
nents. The past 10 years have been challenging but no
more so than will be the future. 
Dr. Fauci is director of the National Institute of Allergy and
Infectious Diseases (NIAID) of the National Institutes of Health,
which is part of the Department of Health and Human Services,
Bethesda, Maryland. At NIAID, Dr. Fauci oversees basic and
applied research to prevent, diagnose, and treat infectious and
immune-mediated illnesses such as HIV/AIDS and other sexual-
ly transmitted diseases, illness from potential agents of bioterror-
ism, tuberculosis, malaria, autoimmune disorders, asthma, and
allergies.
References
1. Morens DM, Folkers GK, Fauci, AS. The challenge of emerging and
re-emerging infectious diseases. Nature. 2004;430:242–9.
2. Fauci AS. Infectious diseases: considerations for the 21st century.
Clin Infect Dis. 2001;32:675–85. 
3. Institute of Medicine. Microbial threats to health: emergence, detec-
tion and response. Washington, DC: The Institute; 2003. 
4. Infectious Diseases Society of America. Bad bugs, no drugs as antibi-
otic discovery stagnates. A public health crisis brews. Washington,
DC: The Society; 2004. 
5. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA,
Butler JC, et al. Investigation of bioterrorism-related anthrax, United
States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:
1019–28. 
6. World Health Organization. The world health report 2004–changing
history. Geneva: The Organization; 2004. 
7.  UNAIDS. 2004 report on the global AIDS epidemic: 4th global
report. [cited 2005 Feb 16]. Available from http://www.unaids.
org/bangkok2004/report.html 
8. Centers for Disease Control and Prevention. HIV/AIDS surveillance
report 2003. Atlanta: The Centers; 2003.
9. Fauci, AS. HIV and AIDS: 20 years of science. Nat Med. 2003;9:
839–43.
10. Graham BS, Mascola JR. Lessons from failure—preparing for future
HIV-1 vaccine efficacy trials. J Infect Dis. 2005;191:647–9.
11. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, et
al. The need for a global HIV vaccine enterprise. Science.
2003;300:2036–9.
12. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et
al. Genome sequence of the human malaria parasite Plasmodium fal-
ciparum. Nature. 2002;419:498–511. 
13.  Holt R Subramanian GM, Halpern A, Sutton GG, Charlab R,
Nusskern DR, et al., The genome sequence of the malaria mosquito
Anopheles gambiae. Science. 2002;298:129–49. 
14. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in
Plasmodium falciparum malaria parasites conferred by pfcrt muta-
tions. Science. 2002;298:210–3. 
15. Johnson, DJ, Ficock DA, Mungthin M, Lakshmanan V, Sidhu ABS,
Bray PG, et al. Evidence for a central role for PfCRT in conferring
Plasmodium falciparum resistance to diverse antimalarial agents.
Mol Cell. 2004;15:867–77. 
16. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial
drug discovery: efficacy models for compound screening. Nat Rev
Drug Discov. 2004;3:509–20.
17.  Jacobs-Lorena M. Interrupting malaria transmission by genetic
manipulation of anopheline mosquitoes. J Vector Borne Dis.
2003;40:73–7.
18. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al.
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falci-
parum infection and disease in young African children: randomized
controlled trial. Lancet. 2004;364:1411–20. 
19. World Health Organization. Portfolio of malaria vaccines currently in
development, October, 2004. [cited 2005 Feb 16]. Available from
http://www.who.int/vaccine_research/documents/en/malaria_table.
pdf 
20.  Reed SG, Alderson MR, Dalemans W, Lobet Y, Skeiky YAW.
Prospects for a better vaccine against tuberculosis. Tuberculosis.
2003;83:213–9. 
21. Butcher PD. Microarrays for Mycobacterium tuberculosis.
Tuberculosis. 2004;84:131–7. 
22. Goguet de la Salmoniere YO, Kim CC, Tsolaki AG, Pym AS, Siegrist
MS, Small PM. High-throughput method for detecting genomic-dele-
tion polymorphisms. J Clin Microbiol. 2004;42:2913–8.
23. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L,
Dillon DC, et al. Differential immune responses and protective effi-
cacy induced by components of a tuberculosis polyprotein vaccine,
Mtb72F, delivered as naked DNAor recombinant protein. J Immunol.
2004;172:7618–28.
24. Horwitz MA, Harth G. A new vaccine against tuberculosis affords
greater survival after challenge than the current vaccine in the guinea
pig model of pulmonary tuberculosis. Infect Immun. 2003;
71:1672–9.
25. National Institute of Allergy and Infectious Diseases. Tuberculosis:
ancient enemy, present threat. [cited 2005 Feb 16]. Available from
http://www2.niaid.nih.gov/newsroom/focuson/tb02/tb.htm 
PERSPECTIVE
524 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 4, April 200526. Centers for Disease Control and Prevention. Influenza Web page.
Available from http://www.cdc.gov/flu/ 
27. World Health Organization. Influenza Web page. [cited 2005 Feb 16].
Available from http://www.who.int/topics/influenza/en/ 
28. National Institute of Allergy and Infectious Diseases. Press releases,
May 27, 2004 and August 17, 2004. [cited 2005 Feb 16]. Available
from http://www2.niaid.nih.gov/Newsroom/Releases/news.htm?
year=2004 
29. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova
EA, et al. Responsiveness to a pandemic alert: use of reverse genet-
ics for rapid development of influenza vaccines. Lancet.
2004;363:1099–103. 
30. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high
virulence of Hong Kong H5N1 influenza A viruses. Science.
2001;293:1840–2. 
31. Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, et
al. Enhanced virulence of influenza A viruses with the haemagglu-
tinin of the 1918 pandemic virus. Nature. 2004;431:703–7. 
32. Maassab HF, Francis T Jr, Davenport FM, Hennessy AV, Minuse E,
Anderson G. Laboratory and clinical characteristics of attenuated
strains of influenza virus. Bull World Health Organ. 1969;41:589–94.
33. Harper SA, Fukuda K, Cox NJ. Using live, attenuated influenza vac-
cine for prevention and control of influenza: supplemental recom-
mendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR Recomm Rep. 2003;52(RR-13):1–8.
34. Komar N. West Nile virus: epidemiology and ecology in North
America. Adv Virus Res. 2003;61:185–234. 
35. Hall RA, Khromykh AA. West Nile virus vaccines. Expert Opin Biol
Ther. 2004;4:1295–305. 
36. Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile
virus encephalitis with intravenous immunoglobulin. Emerg Infect
Dis. 2001;7:759.
37. Borovsky D. Trypsin-modulating oostatic factor: a potential new lar-
vicide for mosquito control. J Exp Biol. 2003;206:3869–75.
38. National Institute of Allergy and Infectious Diseases. NIAID research
on severe acute respiratory syndrome (SARS). [cited 2005 Feb 16].
Available from http://www.niaid.nih.gov/factsheets/sars.htm
39. Yang Z, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, et
al. ADNAvaccine induces SARS coronavirus neutralization and pro-
tective immunity in mice. Nature. 2004;428:561–4. 
40. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR,
et al. Severe acute respiratory syndrome coronavirus spike protein
expressed by attenuated vaccinia virus protectively immunizes mice.
Proc Natl Acad Sci U S A. 2004;101:6641–6.
41. Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St
Claire M, et al. Mucosal immunisation of African green monkeys
(Cercopithecus aethiops) with an attenuated parainfluenza virus
expressing the SARS coronavirus spike protein for the prevention of
SARS. Lancet. 2004;363:2122–7. 
42. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, et al.
Prior infection and passive transfer of neutralizing antibody prevent
replication of severe acute respiratory syndrome coronavirus in the
respiratory tract of mice. J Virology. 2004;78:3572–7. 
43. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y,
Gismondo MR, et al. An efficient method to make human monoclon-
al antibodies from memory B cells: potent neutralization of SARS
coronavirus. Nat Med. 2004;10:871–5.
44. National Institute of Allergy and Infectious Diseases. NIAID biode-
fense research. [cited 2005 Feb 16]. Available from http://www2.
niaid.nih.gov/biodefense/
45. National Center for Biotechnology Information. Entrez Genome.
[cited 2005 Feb 16]. Available from http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=Genome 
46. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH,
et al. Immunogenicity of a highly attenuated MVA smallpox vaccine
and protection against monkeypox. Nature. 2004;428:182–5. 
47. Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated smallpox
vaccine protects mice with and without immune deficiencies against
pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A.
2004;101:4590–5.
48. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZL, Roederer M,
et al. Accelerated vaccination for Ebola virus haemorrhagic fever in
non-human primates. Nature. 2003;424:681–4.
49. Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert
Opin Biol Ther. 2004;4:965–73. 
Address for correspondence: Nancy A. Touchette, National Institute of
Allergy and Infectious Diseases, National Institutes of Health, 9000
Rockville Pike, Building 31, Room 7A05, Bethesda, MD 20892, USA;
fax: 301-496-4409; email: ntouchette@niaid.nih.gov 
Emerging Infectious Diseases: an NIAID Perspective
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 4, April 2005 525
http://www.cdc.gov/ncidod/EID/vol1no1/contents.htm
Volume 1, Number 1
January–March 1995